BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11535993)

  • 1. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study.
    Bönig H; Silbermann S; Weller S; Kirschke R; Körholz D; Janssen G; Göbel U; Nürnberger W
    Bone Marrow Transplant; 2001 Aug; 28(3):259-64. PubMed ID: 11535993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
    Kim IH; Park SK; Suh OK; Oh JM
    Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
    Hofmann WK; Seipelt G; Langenhan S; Reutzel R; Schott D; Schoeffski O; Illiger HJ; Hartmann F; Balleisen L; Franke A; Fiedler F; Huber C; Rasche H; Bergmann L; Ganser A; Pott C; Pasold R; Rudolph C; Ottmann OG; Gökbuget N; Hoelzer D
    Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
    Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
    Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia.
    Carlsson G; Ahlin A; Dahllöf G; Elinder G; Henter JI; Palmblad J
    Br J Haematol; 2004 Jul; 126(1):127-32. PubMed ID: 15198743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors.
    Fischer JC; Frick M; Wassmuth R; Platz A; Punzel M; Wernet P
    Br J Haematol; 2005 Sep; 130(5):740-6. PubMed ID: 16115131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH; Heller G; Kramer K; Cheung NK
    Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
    Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
    Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
    Valteau-Couanet D; Faucher C; Aupérin A; Michon J; Milpied N; Boiron JM; Bourhis JH; Gisselbrecht C; Vernant JP; Pinna A; Bendahmane B; Delabarre F; Benhamou E
    Bone Marrow Transplant; 2005 Sep; 36(6):547-52. PubMed ID: 16007101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
    Suh C; Kim HJ; Kim SH; Kim S; Lee SJ; Lee YS; Kim EK; Kim SB; Lee JS; Kim MW; Kim K; Yoon SS
    Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
    Riikonen P; Rahiala J; Salonvaara M; Perkkiö M
    Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency.
    Nissen C
    Eur J Cancer; 1994; 30A Suppl 3():S12-4. PubMed ID: 7535065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.